131 related articles for article (PubMed ID: 34786070)
1. A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling.
Bu W; Li B; Feng L; Feng Q; Hu K; Xu Z; Wang Y; Xi M; Wang H; Yang G; Wu X; Zhu W; Shi J
Am J Transl Res; 2021; 13(10):11439-11449. PubMed ID: 34786070
[TBL] [Abstract][Full Text] [Related]
2. A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway.
Lu K; Li B; Zhang H; Xu Z; Song D; Gao L; Sun H; Li L; Wang Y; Feng Q; Chen G; Hu L; Wei R; Xie Y; Yu D; Wu X; Zhu W; Shi J
Signal Transduct Target Ther; 2020 Apr; 5(1):31. PubMed ID: 32296013
[TBL] [Abstract][Full Text] [Related]
3. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
4. DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2.
Kong Y; Li B; Chang S; Gao L; Xu Z; He W; Yang G; Xie B; Chen G; Hu L; Lu K; Wang Y; Wu X; Zhu W; Shi J
Cancer Manag Res; 2019; 11():4797-4808. PubMed ID: 31213901
[No Abstract] [Full Text] [Related]
5. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
He W; Fu Y; Zheng Y; Wang X; Liu B; Zeng J
BMC Cancer; 2021 Feb; 21(1):125. PubMed ID: 33549034
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.
Gao L; Li B; Yang G; Liu P; Lan X; Chang S; Tao Y; Xu Z; Xie B; Sun X; Wang Y; Hu L; Yu D; Xie Y; Bu W; Wu X; Zhu W; Shi J
Cancer Lett; 2018 May; 421():135-144. PubMed ID: 29428642
[TBL] [Abstract][Full Text] [Related]
7. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
[TBL] [Abstract][Full Text] [Related]
8. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
9. Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.
Wu Z; Zhan Y; Wang L; Tong J; Zhang L; Lin M; Jin X; Jiang L; Lou Y; Qiu Y
Biomed Pharmacother; 2020 Oct; 130():110556. PubMed ID: 32763815
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
11. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
12. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
13. A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling.
Song Y; Dou H; Wang P; Zhao S; Wang T; Gong W; Zhao J; Li E; Tan R; Hou Y
Cancer Biol Ther; 2014 Oct; 15(10):1423-30. PubMed ID: 25046358
[TBL] [Abstract][Full Text] [Related]
14. A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma.
Zhang Z; Hao C; Zhang R; Pei X; Li J; Wang L
Cell Cycle; 2020 Aug; 19(16):2063-2073. PubMed ID: 32677544
[TBL] [Abstract][Full Text] [Related]
15. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
[TBL] [Abstract][Full Text] [Related]
16. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer.
Tang Q; Wu L; Xu M; Yan D; Shao J; Yan S
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1368-1379. PubMed ID: 32763454
[TBL] [Abstract][Full Text] [Related]
17. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Jakubikova J; Cervi D; Ooi M; Kim K; Nahar S; Klippel S; Cholujova D; Leiba M; Daley JF; Delmore J; Negri J; Blotta S; McMillin DW; Hideshima T; Richardson PG; Sedlak J; Anderson KC; Mitsiades CS
Haematologica; 2011 Aug; 96(8):1170-9. PubMed ID: 21712538
[TBL] [Abstract][Full Text] [Related]
19. Targeting of mTORC1/2 by dihydroevocarpine induces cytotoxicity in acute myeloid leukemia.
Zhang S; Xiong Y; Zhang Y; Zhao H
J Cell Physiol; 2019 Aug; 234(8):13032-13041. PubMed ID: 30548613
[TBL] [Abstract][Full Text] [Related]
20. Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.
Xiao W; Xu Z; Chang S; Li B; Yu D; Wu H; Xie Y; Wang Y; Xie B; Sun X; Kong Y; Lan X; Bu W; Chen G; Gao L; Wu X; Shi J; Zhu W
Cancer Lett; 2019 Mar; 444():45-59. PubMed ID: 30583070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
